Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Authors: Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, Froylán López López, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip - The Lancet 2022 cited by 221